News & Updates

A dedicated team of healthcare professionals recently treated a patient with a rare type of slow-growing, soft tissue cancer.

In the treatment of individuals with early symptomatic Alzheimer's disease and amyloid and tau pathology, the immunoglobulin G1 monoclonal antibody donanemab helps slow clinical progression, according to the results of the phase III TRAILBLAZER-ALZ 2 study.

Factors such as older age (>65 years), ventilator use, and higher comorbidity all contribute to increased mortality risk with COVID-19 among patients with epilepsy, as reported in a study.

A study with 14-year follow-up has pointed to baseline small vessel disease (SVD) severity and SVD progression as independent predictors of dementia.

The gut microbiota-derived metabolite trimethylamine-N-oxide (TMAO) is significantly associated with the risk of stroke, according to a study.